April 21, 2017 - By Michael Collier
Analysts expect Aequus Pharmaceuticals Inc (CVE:AQS) to report $0.00 EPS on May, 5. About 56,400 shares traded. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since March 22, 2017 and is uptrending. It has underperformed by 4.82% the S&P500.
Statoil Asa (NYSE:STO) had an increase of 10.68% in short interest. STO’s SI was 7.27M shares in April as released by FINRA. Its up 10.68% from 6.56 million shares previously. With 2.35 million avg volume, 3 days are for Statoil Asa (NYSE:STO)’s short sellers to cover STO’s short positions. The SI to Statoil Asa’s float is 0.67%. About 1.09 million shares traded. Statoil ASA(ADR) (NYSE:STO) has risen 9.00% since September 14, 2016 and is uptrending. It has underperformed by 1.82% the S&P500.
Statoil ASA is an energy company. The company has market cap of $53.25 billion. The Firm is engaged in gas and oil exploration and production activities. It currently has negative earnings. The Company’s divisions include Development and Production Norway (DPN), Development and Production International (DPI), Marketing, Midstream and Processing (MMP) and Other.
Among 13 analysts covering Statoil Asa (NYSE:STO), 5 have Buy rating, 4 Sell and 4 Hold. Therefore 38% are positive. Statoil Asa had 15 analyst reports since September 11, 2015 according to SRatingsIntel. The company was upgraded on Friday, September 16 by Bank of America. The firm earned “Hold” rating on Friday, March 11 by SEB Equity Research. On Thursday, May 26 the stock rating was downgraded by HSBC to “Neutral”. The rating was downgraded by Morgan Stanley on Friday, July 22 to “Equal-Weight”. The company was downgraded on Tuesday, June 21 by Deutsche Bank. The firm has “Reduce” rating by Swedbank given on Wednesday, March 9. The stock has “Sector Outperform” rating by Howard Weil on Monday, October 12. The rating was downgraded by Morgan Stanley on Friday, September 9 to “Underweight”. Simmons & Co downgraded Statoil ASA(ADR) (NYSE:STO) on Thursday, January 21 to “Neutral” rating. The stock of Statoil ASA(ADR) (NYSE:STO) earned “Underperform” rating by RBC Capital Markets on Tuesday, May 31.
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical firm focused on developing and commercializing products. The company has market cap of $21.02 million. The Firm operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. It currently has negative earnings. The Company’s products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release , which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.